Bladder cancer is not a single disease. Tumours that appear similar under a microscope can behave very differently, relapse at different rates and respond to entirely different treatments. Urothelial carcinoma, the most common form, is shaped by a complex mixture of genetic alterations, immune activity and changes in the tumour environment. Traditional clinical factors—such as tumour stage, grade, recurrence history and lymph-node involvement—remain essential, but they cannot fully explain this biological diversity. Biomarker testing offers a way to add that missing layer of information.

The group’s central message is that testing must be connected to a clinical decision. A biomarker is “actionable” when its result can influence treatment, surveillance or eligibility for a clinical trial. In bladder cancer, this may include alterations in the fibroblast growth factor receptor pathway, especially FGFR3, which can make some advanced tumours susceptible to FGFR-directed therapy. Other potentially relevant markers include programmed death-ligand 1, or PD-L1, which can help inform the use of immune checkpoint inhibitors in selected settings, as well as DNA repair defects, microsatellite instability and mismatch-repair deficiency, all of which may indicate an unusual sensitivity to immunotherapy.

The recommendations also highlight the importance of assessing HER2 biology, an area that has become increasingly relevant as antibody–drug conjugates and other targeted approaches expand. HER2 testing is not simply a matter of recording whether the protein is present or absent. Different laboratory methods can measure protein expression or gene amplification, and the result may depend on the assay, scoring system and quality of the tissue sample. Such technical details can determine whether a patient is correctly identified for a treatment opportunity, making standardized pathology procedures a critical part of precision oncology.

Timing is another major issue. Molecular information may be useful at diagnosis, before surgery, after recurrence or when metastatic disease develops, but the most informative sample can change as the cancer evolves. A tumour treated with chemotherapy, radiation, immunotherapy or targeted drugs may acquire new genetic features that were not present in the original biopsy. For this reason, the group supports a dynamic approach in which previously collected tissue is used when appropriate, while fresh tumour material—or, in selected circumstances, circulating tumour DNA from a blood sample—is considered when the disease changes.

This evolving biology creates a practical challenge for clinicians. A negative result from an old biopsy does not necessarily mean that a target is absent from a later tumour, just as a positive result may not guarantee that a treatment will work. Biomarkers are probabilities, not biological promises. Their interpretation must be combined with disease stage, previous therapies, organ function, patient preferences and the strength of evidence supporting a particular drug. The recommendations therefore emphasize multidisciplinary decision-making involving urologists, medical oncologists, pathologists, radiologists and molecular specialists.

The article also addresses the risk of fragmented testing. In many health systems, biomarker analysis is performed only after a patient has progressed through several lines of therapy, by which time an important treatment window may have passed. Tests may also be ordered inconsistently, interpreted using different criteria or delayed by limited access to specialized laboratories. The International Bladder Cancer Group calls for clearer testing pathways, validated assays and reporting systems that explain not only the molecular finding but also its clinical meaning, the available treatment options and the level of evidence behind them.

For patients, the shift could transform conversations about treatment. Instead of receiving a broadly defined diagnosis followed by a standard sequence of therapies, some individuals may be offered a strategy tailored to the molecular vulnerabilities of their cancer. A person whose tumour contains an actionable FGFR3 alteration, for example, may be considered for a pathway-specific drug, while another patient with immune-related biomarkers could be evaluated for checkpoint blockade. Those without an established target may be directed toward trials testing new combinations, novel antibody–drug conjugates or strategies designed to overcome resistance.

Yet precision medicine will not succeed through testing alone. The group stresses that biomarkers must be clinically validated, accessible and used equitably. Many promising molecular signals have not produced reliable benefits in large trials, and some tests remain too expensive or technically demanding for routine use. There is also a danger that unequal access to genomic profiling will widen existing differences in cancer outcomes. Integrating biomarkers into care therefore requires investment in laboratory quality, data interpretation, clinician education and reimbursement, alongside transparent communication with patients.

The wider significance of the recommendations reaches beyond bladder cancer. They represent a blueprint for moving from a one-size-fits-most model toward treatment decisions that reflect the biological identity of each tumour. As more targeted therapies and immunotherapies enter the clinic, the value of a biomarker will depend increasingly on how rapidly and accurately it can connect a patient to the right option. The International Bladder Cancer Group’s message is clear: molecular testing should not be an afterthought in bladder cancer care. It should become part of the clinical infrastructure that links diagnosis, treatment selection and the next generation of research.

Subject of Research: Bladder cancer biomarkers and their integration into clinical diagnosis, treatment selection, surveillance and precision oncology.

Article Title: Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

Article References: Hensley, P.J., Teoh, J.Y.C., Li, R. et al. Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01179-y

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01179-y

Keywords: bladder cancer, urothelial carcinoma, biomarkers, precision oncology, FGFR3, HER2, PD-L1, immunotherapy, targeted therapy, molecular testing, circulating tumour DNA, cancer care.

The researchers commenced by harnessing large-scale bladder cancer datasets from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), integrating these extensive molecular profiles with curated stemness gene sets sourced from the StemChecker database. Employing consensus clustering, a robust machine learning algorithm, they segmented patients based on the enrichment scores of stemness-related genes. This approach transcended traditional sampling biases, enabling a reproducible and biologically meaningful classification reflecting underlying tumor biology. Simultaneously, the team applied the One-Class Logistic Regression (OCLR) algorithm to compute the mRNA expression-based stemness index (mRNAsi), quantifying the self-renewal capacity of each tumor sample at a molecular level.

The meticulous analysis unearthed two discrete bladder cancer stemness subtypes, each characterized by distinctive genomic, immunologic, and therapeutic response profiles. Patients categorized within the first subtype exhibited elevated mRNAsi scores that paradoxically correlated with more favorable overall survival. This subtype manifested an immunologically active tumor microenvironment, hallmarked by abundant antitumor immune cell infiltration, potentially enhancing responsiveness to emerging immunotherapies. Conversely, the second subtype demonstrated marked genomic instability, including increased aneuploidy and homologous recombination defects, coupled with a heightened tumor mutation burden. Clinically, this group showed increased susceptibility to conventional chemotherapeutic agents rather than immunotherapy, underscoring the heterogeneity of treatment responses linked to tumor stemness.

Driven by the imperative for clinical translation, the team constructed a predictive classifier distinguishing these stemness subtypes through a rigorous machine learning paradigm incorporating LASSO regression, random forest algorithms, and multivariate logistic regression. This multifaceted strategy distilled an initial pool of candidates to six key differentially expressed genes with the highest predictive power. Validation across multiple independent GEO datasets and two non-muscle invasive bladder cancer cohorts confirmed the classifier’s robustness and prognostic accuracy, solidifying its potential as a practical tool in clinical oncology to stratify patients for tailored therapies.

Among the pivotal classifier genes, TNFAIP6 emerged as a critical mediator of bladder cancer stemness, verified through experimental assays including tumor sphere formation and western blot analyses. Silencing of TNFAIP6 significantly impaired the stem-like properties of bladder cancer cells, substantiating its functional importance. Intriguingly, TNFAIP6 knockdown also sensitized tumor cells to frontline chemotherapeutic drugs such as cisplatin, docetaxel, and paclitaxel, suggesting an actionable vulnerability that could be exploited to overcome chemoresistance. Moreover, repression of TNFAIP6 led to downregulation of the immune checkpoint gene PD-L1, highlighting its potential role in modulating tumor immune evasion.

The integration of computational predictions with wet-lab validations underscores a paradigm shift in cancer research, where data-driven discoveries refine our molecular understanding and catalyze therapeutic innovations. By elucidating the dualistic nature of bladder cancer stemness—where subtype 1’s immune-engaged state contrasts with subtype 2’s genomic instability-driven vulnerability—the study opens new avenues to personalize treatment protocols. Precision oncology, long the aspirational frontier, stands to benefit immensely from such stratified approaches, ensuring patients receive immunotherapy or chemotherapy tailored to their tumor’s stemness landscape.

Importantly, this research sheds light on the intricate interplay between tumor stemness and the tumor microenvironment. The antitumor immune milieu observed in stemness subtype 1 could be leveraged to optimize immunotherapeutic regimens, including checkpoint inhibitors that have revolutionized bladder cancer care in recent years. Simultaneously, patients harboring tumors classified within subtype 2 might gain enhanced efficacy through DNA damage repair-targeted therapies given their homologous recombination deficiencies, complementing standard chemotherapy.

Beyond prognostic and predictive dimensions, this study positions TNFAIP6 as a promising molecular target for future drug development. Its role in sustaining stemness and modulating immune checkpoints implicates it as a dual facilitator of tumor progression and immune suppression. Therapeutic strategies aimed at TNFAIP6 inhibition could potentially dismantle cancer stem cell reservoirs while improving the tumor’s immunogenicity, thus creating synergistic effects with existing modalities.

The authors acknowledge the complexity intrinsic to cancer stemness, emphasizing that the binary classification, while enlightening, represents a simplification of a spectrum of cellular states within bladder tumors. Nevertheless, the reproducibility of the classifier across diverse cohorts and the corroborative functional assays signify a robust framework for subsequent translational studies. Further investigations will undoubtedly refine these insights, possibly incorporating single-cell transcriptomics and proteomics to resolve heterogeneity at an even finer scale.

Clinical integration of this stemness subtype classifier may revolutionize patient management by enabling oncologists to predict not only prognosis but also optimal therapeutic avenues before treatment initiation. This preemptive stratification will minimize unnecessary exposure to ineffective therapies, reduce adverse effects, and improve survival rates. Additionally, the classifier could serve as a dynamic biomarker for monitoring therapeutic response and disease progression, underpinning adaptive treatment strategies.

From a broader perspective, the melding of machine learning with molecular oncology exemplifies the transformative potential of artificial intelligence in medicine. As datasets burgeon and computational algorithms mature, similar approaches could redefine classification schemas across myriad cancers, tailoring therapies with unprecedented precision.

In conclusion, this pioneering study offers compelling evidence that the molecular characterization of bladder cancer stemness through machine learning not only enhances our biological comprehension but also provides tangible clinical tools. The identification of two distinct stemness subtypes, coupled with a validated genetic classifier and functional exploration of TNFAIP6, lays the groundwork for next-generation therapies. As the oncology community grapples with the challenges of tumor heterogeneity and treatment resistance, such integrative, data-driven innovations herald a new chapter in the fight against bladder cancer.

Subject of Research: Bladder cancer stemness characterization and molecular classification using machine learning algorithms.

Article Title: Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer.

Article References:
Qiu, H., Deng, X., Zha, J. et al. Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer. BMC Cancer 25, 717 (2025). https://doi.org/10.1186/s12885-025-14109-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14109-9